ArticleTranslational psychiatry2026
Blood IL-6 is a critical trigger of depressive symptoms in a mouse model for human atopic dermatitis.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Patients with atopic dermatitis (AD) often suffer from mental health issues such as depression. Crosstalk between proinflammatory cytokines and hippocampal circuits may be a potent risk factor for behavioral abnormalities in depression, including anxiety, and mood disorders, which negatively controlled hippocampal neurogenesis via the upregulation of several proinflammatory cytokines. However, the mechanisms by which AD notably contribute to the development of depression are poorly understood. We found that increased IL-6 and soluble IL-6Rα (sIL-6Rα) in the peripheral blood specifically disrupted the blood-brain barrier and triggered depressive symptoms in NC/Tnd mice with spontaneous AD. The skin severity and depressive behavior correlated with markedly reduced numbers of doublecortin (DCX)-positive immature neurons in the hippocampus. Parabiotic pairs of mice with AD and unaffected mice showed disruption of hippocampal neurogenesis in the unaffected mice. Injection of neutralizing mAb against IL-6 significantly improved depressive behavioral signs and hippocampal neurogenesis. Furthermore, house dust mite-induced dermatitis gave rise to no depressive phenotypes in IL-6-deficient mice. Single-cell RNA sequencing analysis showed high expression of IL-6Rβ, unlike IL-6Rα, in hippocampal cells isolated from NC/Tnd mice. Addition of IL-6 and sIL-6Rα to neuronal progenitor cells cultured from the murine hippocampal dentate gyrus significantly reduced the number of DCX-positive cells, whereas IL-6 alone had no effect. Overall, these findings suggest that increased peripheral blood IL-6 and sIL-6Rα following atopic inflammation inhibits hippocampal immature neurogenesis via IL-6Rβ and is a critical risk factor for the development of mood and behavioral disorders in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.